CATO vs RCUS

For growth investors, Arcus Biosciences, Inc.

(RCUS) is the stronger pick with -4. 3% revenue growth year-over-year, versus -8. 2% for The Cato Corporation (CATO). Analysts rate Arcus Biosciences, Inc. (RCUS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -60. 4% for The Cato Corporation (CATO). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus CATO's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Cato Corporation (CATO) is the lower-risk stock at 0.

88β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 121% more volatile than CATO relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 90% for The Cato Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcus Biosciences, Inc.

(RCUS) is pulling ahead at -4. 3% versus -8. 2% for The Cato Corporation (CATO). On earnings-per-share growth, the picture is similar: The Cato Corporation grew EPS 17. 1% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Cato Corporation (CATO) is the more profitable company, earning -2.

9% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -2. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CATO leads at -4. 2% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CATO (18.

7% yield) pays a dividend. RCUS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Cato Corporation (CATO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

88), 18. 7% yield). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CATO: -72. 3%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CATO (Consumer Cyclical) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CATO is a small-cap income-oriented stock; RCUS is a small-cap quality compounder stock. CATO pays a dividend while RCUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.